Caroline Seymour

Jonathan Mizrahi, MD, discusses recent pivotal data in colorectal cancer and its impact on personalized care in the treatment paradigm.

Benjamin Leon Musher, MD, reflects on the progress that has been made in hepatocellular carcinoma and highlights promising combinations that are emerging in the space.

Prasad S. Adusumilli, MD, sheds light on the preliminary phase I data from a trial of CAR T-cell therapy in malignant pleural disease from mesothelioma.

Although there are several maintenance strategies to consider for patients with advanced ovarian cancer, the decision of which approach to pursue largely depends on the molecular makeup of an individual patient’s tumor.

Chrisann Kyi, MD, discusses the utility of PARP inhibitors in the primary treatment and maintenance settings for patients with recurrent ovarian cancer and the next steps that lie ahead.

Jason A. Konner, MD, sheds light on the current treatment landscape for patients with platinum-sensitive and platinum-resistant/recurrent ovarian cancer

Britta Weigelt, PhD, discusses germline and somatic mutations in ovarian cancer that confer potential implications on treatment decisions, as well as those that carry an added cancer risk.

Dmitriy Zamarin, MD, PhD, discusses ongoing research regarding immunotherapy and synergistic strategies also under investigation in advanced ovarian cancer.

Jordan D. Berlin, MD, sheds light on current and future directions in the field of locally advanced pancreatic cancer.

Paul Sabbatini, MD, clarifies where the field stands regarding the use of bevacizumab, intraperitoneal therapy, and a 3-week dosing schedule of chemotherapy versus a weekly dose-dense regimen in the frontline setting of newly diagnosed ovarian cancer.

J. Stuart Salmon, MD, highlights first-, second-, and third-line treatment options for patients with gastric and gastroesophageal cancer following recent clinical trial findings and regulatory approvals.

Terrence J. Bradley, MD, discusses approved and investigational agents that patients with myelofibrosis and polycythemia vera can turn to.

Kunal C. Kadakia, MD, highlight key takeaways from the the PROMID, CLARINET, and NETTER-1 trials and explains how their findings have been applied to clinical practice.

The frontline combination of fulvestrant and anastrozole resulted in a sustained benefit in progression-free survival and a significant improvement in overall survival compared with anastrozole alone in patients with postmenopausal, HR–positive metastatic breast cancer, according to long-term results of the SWOG S0226 trial.

Although it has been difficult to identify a specific target for triple-negative breast cancer, several therapeutic classes are showing great promise.

The use of prophylactic cranial irradiation failed to demonstrate a statistically significant improvement in overall survival over observation in patients with locally advanced stage III non–small cell lung cancer; however, the modality did improve disease-free survival and decreased the risk of brain metastasis.

Mohamed E. Salem, MD, highlights ongoing research efforts to potentially improve survival in patients with metastatic colorectal cancer.

Childhood cancer survivors who had lived 5 or more years from their primary malignancy are at an increased risk of developing skin cancer compared with the general population.

Melody A. Cobleigh, MD, sheds light on novel treatment approaches for patients with HER2-positive breast cancer that are under investigation as well as strategies that have already been incorporated into practice.

Ruta D. Rao, MD, highlights the importance of determining risk for recurrence and its impact on conversations about extended adjuvant endocrine therapy and the use of chemotherapy in patients with early-stage HR-positive, HER2-negative breast cancer.

Stephen D. Nimer, MD, sheds light on new strategies and trends in the treatment of patients with hematologic malignancies.

Iman Imanirad, MD, discusses these trials in depth and their impact on patients with refractory metastatic colorectal cancer.

Damian Laber, MD, provides a brief history of the trials that led to current frontline and second-line standards for patients with metastatic pancreatic cancer and shares his hope for the future of the treatment paradigm.

Childhood cancer is significantly underdiagnosed—especially in south Asia and sub-Saharan Africa—underscoring the need for stronger health systems and the expansion of universal health coverage, according to an analysis published in Lancet Oncology.

Izidore S. Lossos, MD, discusses the current pillars of care and barriers in the treatment of patients with early-stage and advanced follicular lymphoma, as well as mantle cell lymphoma.

Thomas Powles, MBBS, MRCP, MD, highlights key takeaways from pivotal trials and discusses how they impact the ever-changing landscape of metastatic renal cell carcinoma.

Richard Kim, MD, discusses the therapeutic landscape of advanced hepatocellular carcinoma in light of recent findings and highlighted anticipated research in the field.

Andre Goy, MD, MS, shares insight on the stratification of patients with mantle cell lymphoma and other molecular markers that are being applied towards optimal treatment decisions in this disease.

Saad Z. Usmani, MD, shares insight on approaches to early relapse in myeloma given the evolution of frontline treatment advances.

Hope E. Uronis, MD, MHS, sheds light on therapeutic classes in gastric and esophageal cancer and the trials that have demonstrated their utility and refined their applicability across settings, subpopulations, and histologies of gastric/GEJ cancer.